Times up to demonstrate a difference is current DES platforms

Area of Science:

• Cardiovascular medicine
• Medical devices
• Interventional cardiology

Background:

• Current durable polymer drug-eluting stents (DES) demonstrate sustained efficacy and safety up to 5 years.
• The Orsiro DES features a bioresorbable polymer and ultra-thin struts, aiming to enhance DES safety.
• An all-comers trial was conducted to evaluate the 3-year outcomes of the Orsiro DES.

Discussion:

• The study compared the 3-year clinical outcomes of the Orsiro DES against a durable polymer zotarolimus-eluting stent.
• Findings indicate similar safety and efficacy profiles between the Orsiro DES and the comparator stent.
• The bioresorbable polymer and ultra-thin strut design of the Orsiro DES warrant further investigation for potential safety benefits.

Key Insights:

• The Orsiro DES, utilizing a bioresorbable polymer, achieved comparable 3-year outcomes to durable polymer DES in an all-comers population.
• No significant differences in safety and efficacy were observed between the Orsiro DES and the zotarolimus-eluting stent at the 3-year follow-up.
• The results support the potential of bioresorbable polymer DES to match the performance of established durable polymer DES.

Outlook:

• Further long-term studies are needed to fully elucidate the safety and efficacy advantages of bioresorbable polymer DES.
• Investigating patient subgroups may reveal specific benefits of the Orsiro DES design.
• Continued evaluation of novel DES technologies is crucial for advancing cardiovascular treatment.